Parexel has published findings and recommendations for making clinical research more accessible and welcoming for transgender and nonbinary people.
While there are nearly 1.6 million transgender people in the US alone, of the thousands interventional clinical trial results published on PubMed from 2018 to 2022, Parexel notes less than one percent included participation of transgender and nonbinary patients. Many have deep-rooted reservations about healthcare and worry the risks of participating in a clinical trial would outweigh its benefits.
Through collaborating with partners and their patient advisory council and extensive research, Parexel identified five roadblocks to participation and eight solutions for designing more equitable clinical trials for transgender and nonbinary patients.
Download the study here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.